Mostrar el registro sencillo del ítem

Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia

dc.contributor.authorGiménez, N.
dc.contributor.authorMartínez Trillos, A.
dc.contributor.authorMontraveta, A.
dc.contributor.authorSuárez Puente, Xosé Antón 
dc.contributor.authorLópez Otín, Carlos 
dc.date.accessioned2019-08-21T07:34:17Z
dc.date.available2019-08-21T07:34:17Z
dc.date.issued2019
dc.identifier.citationHaematologica, 104(3), p. 576-586 (2019); doi:10.3324/haematol.2018.196931
dc.identifier.issn0390-6078
dc.identifier.urihttp://hdl.handle.net/10651/52304
dc.description.sponsorshipThis study was supported by the Ministerio de Economía y Competitividad, Grant n. SAF2015-67633-R ,and PI16/00420 which are part of Plan Nacional de I+D+I and are co-financed by the European Regional Development Fund (FEDER-“Una manera de hacer Europa”) and the CERCA program from Generalitat Catalunya. European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement n. 306240; Generalitat de Catalunya Suport Grups de Recerca AGAUR 2017-SGR1009, and Departament de Salut (SLT002-16-00350), Instituto de Salud Carlos III (ISCIII) International Cancer Genome Consortium for Chronic Lymphocytic Leukemia (ICGC-CLL Genome Project), and project PM15/00007, which is part of Plan Nacional de I+D+I and are co-financed by FEDER. NG is a recipient of a predoctoral fellowship from Agaur and EC is an Academia Researcher of the "Institució Catalana de Recerca i Estudis Avançats" (ICREA) of the Generalitat de Catalunya.
dc.description.statementofresponsibilityGiménez, N., Martínez-Trillos, A., Montraveta, A., Lopez-Guerra, M., Rosich, L., Nadeu, F., Valero, J.G., Aymerich, M., Magnano, L., Rozman, M., Matutes, E., Delgado, J., Baumann, T., Gine, E., González, M., Alcoceba, M., Terol, M.J., Navarro, B., Colado, E., Payer, A.R., Puente, X.S., López-Otín, C., Lopez-Guillermo, A., Campo, E., Colomer, D., Villamor, N.
dc.format.extentp. 576-586
dc.language.isoeng
dc.relation.ispartofHaematologica, 104
dc.rights© 2019 Ferrata Storti Foundation
dc.rightsCC Reconocimiento - No Comercial 4.0 Internacional
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourceScopus
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85063064850&doi=10.3324%2fhaematol.2018.196931&partnerID=40&md5=f7b590064a0c26d1f8d5c8d1e7a2743d
dc.titleMutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia
dc.typejournal article
dc.identifier.doi10.3324/haematol.2018.196931
dc.relation.projectIDMINECO/SAF2015-67633-R
dc.relation.projectIDMINECO/PI16/00420
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FP7/306240
dc.relation.projectIDISCIII/FEDER/PM15/00007
dc.relation.publisherversionhttp://dx.doi.org/10.3324/haematol.2018.196931
dc.rights.accessRightsopen access
dc.type.hasVersionVoR


Ficheros en el ítem

untranslated

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

© 2019 Ferrata Storti Foundation
Este ítem está sujeto a una licencia Creative Commons